Polycythemia Vera – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Polycythemia Vera – Pipeline Review, H2 2018’, provides an overview of the Polycythemia Vera pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera

– The report reviews pipeline therapeutics for Polycythemia Vera by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Polycythemia Vera therapeutics and enlists all their major and minor projects

– The report assesses Polycythemia Vera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Polycythemia Vera

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Polycythemia Vera

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Polycythemia Vera pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Bristol-Myers Squibb Co

Celgene Corp

F. Hoffmann-La Roche Ltd

Gilead Sciences Inc

Italfarmaco SpA

Nerviano Medical Sciences Srl

PharmaEssentia Corp

SELLAS Life Sciences Group Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Polycythemia Vera Overview

Polycythemia Vera Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Polycythemia Vera Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Polycythemia Vera Companies Involved in Therapeutics Development

AbbVie Inc

Bristol-Myers Squibb Co

Celgene Corp

F. Hoffmann-La Roche Ltd

Gilead Sciences Inc

Italfarmaco SpA

Nerviano Medical Sciences Srl

PharmaEssentia Corp

SELLAS Life Sciences Group Inc

Polycythemia Vera Drug Profiles

anagrelide hydrochloride CR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasatinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fedratinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

givinostat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

idasanutlin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

idelalisib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-009 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-012 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-113 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon alfa-2a Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ropeginterferon alfa-2b Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veliparib ER Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polycythemia Vera Dormant Projects

Polycythemia Vera Discontinued Products

Polycythemia Vera Product Development Milestones

Featured News & Press Releases

Jun 11, 2018: AOP Orphan Announces Progress of its European Marketing Authorization Procedure of Ropeginterferon alfa-2b

Dec 11, 2017: Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials

Dec 11, 2017: Italfarmaco Presents Positive Phase II Study Results for Givinostat in Polycythemia Vera Patients at the ASH Annual Meeting

Dec 10, 2017: PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2017

Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting

Nov 27, 2017: Impact Biomedicines to Present Retrospective Data on Fedratinib at the 2017 ASH Annual Meeting

Jun 25, 2017: AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid

Mar 14, 2017: AOP Orphan Pharmaceuticals announces start of EMA marketing authorization application procedure for Ropeginterferon alfa-2b in Polycythemia Vera

Dec 05, 2016: AOP Orphan and PharmaEssentia Announce Pivotal Phase III results for Ropeginterferon alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2016

Nov 28, 2016: PharmaEssentia Announces Phase III PROUD-PV Study Results to be Presented at ASH Annual Meeting Oral Presentation

Sep 12, 2016: Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan

May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012

May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases

Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Polycythemia Vera, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Polycythemia Vera Pipeline by AbbVie Inc, H2 2018

Polycythemia Vera Pipeline by Bristol-Myers Squibb Co, H2 2018

Polycythemia Vera Pipeline by Celgene Corp, H2 2018

Polycythemia Vera Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Polycythemia Vera Pipeline by Gilead Sciences Inc, H2 2018

Polycythemia Vera Pipeline by Italfarmaco SpA, H2 2018

Polycythemia Vera Pipeline by Nerviano Medical Sciences Srl, H2 2018

Polycythemia Vera Pipeline by PharmaEssentia Corp, H2 2018

Polycythemia Vera Pipeline by SELLAS Life Sciences Group Inc, H2 2018

Polycythemia Vera Dormant Projects, H2 2018

Polycythemia Vera Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Polycythemia Vera, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports